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Dementia with Lewy bodies (DLB) is characterised by complex
visual hallucinations. Previously, we used the threshold for eliciting
phosphenes with occipital transcranial magnetic stimulation (TMS)
as a measure of visual cortical excitability.1 Although this threshold
correlated with the severity and frequency of visual hallucinations
in DLB, overall excitability was similar between DLB and controls,
suggesting that early visual areas are functionally intact in DLB.
This was supported by our finding of unaltered cortical activity
in the early visual system (V1, V2/V3), as measured by blood
oxygen level-dependent (BOLD) functional magnetic resonance
imaging (fMRI), in DLB.2 BOLD haemodynamic response has
been suggested to be related to synaptic activity in terms of input
and local processing,3 as well as to neuronal spiking4 arising from
sensory stimulation, and thus may represent the activity in both
excitatory and inhibitory neuronal populations. In contrast, the
neuronal discharge consequent to TMS is likely to be dependent
on the relative balance of excitatory and inhibitory activity within
the area of stimulation. Therefore a positive relationship between
BOLD activity in the early visual system and phosphene threshold
may suggest that inhibition outweighs excitation, whereas a
negative relationship may indicate the opposite. In this paper
we report the interrelationship between fMRI BOLD activity in
the early visual system and visual cortical excitability as measured
using TMS, using previously published data from patients with
DLB and hallucinations and from controls.1,2
Method
Details of participant selection, neuropsychological and neuro-
psychiatric assessment, fMRI and TMS testing are described fully
elsewhere. In the current analysis, we selected participants who
had undergone both fMRI and occipital TMS.1,2 In brief, 16
participants who met criteria for probable DLB5 and who
experienced visual hallucinations at least once in the month before
TMS/fMRI testing were recruited from a community-dwelling
population of patients, along with 19 controls. The study was
approved by the local ethics committee. The DLB diagnosis was
made independently by two experienced senior clinicians.5
Occipital TMS and neuroimaging evaluations were conducted
within 2 weeks of each other.
TMS and imaging protocols are described in the online
supplementary methods.
Results
The DLB and control groups were similar in terms of age, gender
and visual acuity. Unified Parkinson’s Disease Rating Scale
(UPDRS)6 motor scores were significantly higher and cognitive
test and visuoperceptual task scores significantly lower in the
DLB group (online Table DS1).
Phosphenes were elicited in a similar proportion of the control
(17/19, 90%) and DLB groups (14/17, 82%; Fisher exact test,
P=0.66). Across groups, phosphene thresholds were similar (control
group: median 70.7%, interquartile range (IQR) = 44.0%; DLB
group: median 77.2%, IQR= 36.0%, Mann–Whitney U-test
115.5, P=0.23).
There were no differences in V1 or V2/V3 BOLD magnitude
between the control and DLB groups for checkerboard stimulus
(V1: control group, mean 0.41 (s.d. = 0.36); DLB group, mean
0.57 (s.d. = 0.30), P= 0.16. V2/V3 control group: mean 0.68
(s.d. = 0.36); DLB group mean 0.71 (s.d. = 0.29), P= 0.83).
Similarly, there were no perfusion differences in V1 (ml/100 g/
min: control group, mean 33.3 (s.d. = 9.6); DLB group, mean
28.0 (s.d. = 10.5), P=0.20) or V2/V3 (control group, mean 32.1
(s.d. = 8.4), DLB group, mean 27.0 (s.d. = 7.6), P=0.15) between
groups. However, there were significant positive correlations
between the magnitude of the BOLD response (V1 and V2/V3)
to the checkerboard stimulus and phosphene thresholds in the
control group and a significant negative relationship in the DLB
group in both V1 and V2/V3 (V1: control group, r= 0.48,
P= 0.04; DLB group, r=70.71, P=0.002. V2/V3: control group,
r= 0.64, P= 0.003; DLB group, r=70.57, P=0.02, online Fig.
DS1). These relationships remained significant (P50.05) even
with the removal of non-responders (i.e. those participants with
a phosphene threshold greater than 100% of the stimulator
output) except for phosphene threshold v. V2/V3 in the DLB
group. In TMS responders (i.e. those experiencing phosphenes)
BOLD activity was significantly lower in the control group in
V1 compared with the DLB group (control group, mean 0.40
(s.d. = 0.37); DLB group, mean 0.65 (s.d. = 0.25), P= 0.04).
Differences in the slopes for the control v. DLB group for V1
and V2/V3 were highly significant (Fisher r-to-z transformation:
V1, z=3.78, P50.001, V2/V3, z=3.76, P50.001). BOLD activity
was significantly lower in V1 and trending lower in V2/V3 in those
in the DLB group who were on cholinesterase inhibitors (V1:
mean 0.45 (s.d. = 0.24); V2/V3: mean 0.62 (s.d. = 0.10)) compared
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Summary
Alterations in the visual system may underlie visual
hallucinations in dementia with Lewy bodies (DLB). However,
cortical excitability as measured by transcranial magnetic
stimulation (TMS) and functional magnetic resonance imaging
(fMRI) activation of lower visual areas (V1–3) to visual stimuli
appear normal in DLB. We explored the relationship between
TMS-determined phosphene threshold and fMRI-related visual
activation and found a positive relationship between the
two in controls but a negative one in DLB. This double
dissociation suggests a loss of inhibition in the visual
system in DLB, which may predispose individuals to visual
dysfunction and visual hallucinations.
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with those in the DLB group not taking these agents (V1: mean
0.82 (s.d. = 0.28), P=0.02; V2/V3: mean 0.88 (s.d. = 0.33),
P= 0.10) although phosphene thresholds were similar, as was
cerebral perfusion in V1 and V2/V3 between the DLB group on
and off cholinesterase inhibitors (phosphene threshold: mean
76.7% (s.d. = 20.2%) v. 78.2% (s.d. = 21.1%), P=0.90. Perfusion
(ml/100g/min): V1, mean 27.1 (s.d. = 9.7) v. 30.4 (s.d. = 13.7),
P= 0.62; V2/V3, mean 27.4 (s.d. = 7.3) v. mean 25.8 (s.d. = 9.4),
P= 0.73). There was no association between global cognitive
function in the DLB group and phosphene threshold, BOLD
activity or cerebral perfusion in V1 or V2/V3 (P40.13).
Discussion
We report a significant positive relationship between phosphene
threshold and BOLD activity in early visual areas (V1, V2/V3)
in our controls, which suggests that the greater an individual’s
inherent visual cortical excitability, the smaller the visual cortical
activation in response to a simple checkerboard stimulus. This
observation implies that individuals with sensitive visual systems
need less ‘activation’ to an external stimulus. In contrast, the
opposite relationship in DLB infers a breakdown in this dynamic.
Assuming similar visual cortical neuronal populations are
activated by the checkerboard and TMS, then in the controls a
positive relationship between BOLD activity and phosphene
threshold implies inhibition must outweigh excitation, whereas
in DLB this is reversed. If the BOLD signal represents spiking
excitatory neuronal activity,4 then the lack of difference between
groups in mean BOLD activity suggests a loss of inhibition.
There needs to be critical consideration to our interpretations;
our knowledge of the underlying neuronal activity of the BOLD
signal is incomplete3,7 and the BOLD effect reflects not just
neuronal activity but also haemodynamic coupling, which may be
altered with neurodegeneration; ideally cerebrovascular reactivity
would be assessed via a CO2 challenge
8 or similar paradigm.
However, we did not observe any differences in occipital perfusion
between the control and DLB group, and similarly, there was no
relationship between perfusion and either BOLD response or
phosphene threshold. Furthermore, cognitive function in DLB
was not associated with phosphene threshold or any of the neuro-
imaging measures. Thus, although not providing a direct measure
of cerebrovascular reactivity, these findings suggest that the early
visual system in these participants with DLB was similar to
controls.
From the TMS perspective, the origin of phosphene perception
may not be co-localised to the visual cortex and thus the relative
state of the visual cortex may be less crucial to phosphene
perception, although reciprocal connections between early visual
and association areas are likely to be important.9 In addition,
cholinergic function has been implicated in modulating visual
attention and associated BOLD fMRI responses;10 our observation
of differences in BOLD activity between those patients with DLB
taking cholinesterase inhibitors v. those not, supports this and fits
into the broader framework of reported cholinergic receptor
changes in DLB11 as well as changes in occipital metabolism in
individuals with DLB with hallucination amelioration treated with
donepezil.12
Finally, a loss of inhibitory activity in patients might be
expected to decrease phosphene threshold relative to the control
group, something which was not observed. However, it is notable
that for a range of phosphene thresholds, the overall BOLD
response in the DLB group was larger than in the control group,
significantly so for V1 after excluding TMS non-responders
(whose relative level of visual cortical excitability is unclear).
Hence, one could speculate that compensatory mechanisms may
be operating in patients with DLB that attempt to ‘normalise’
the balance of excitation/ inhibition in an underactive early visual
system, in the face of ‘upstream’ pathology in the visual system
thus leading to a maintenance of the phosphene threshold within
a normative range and possibly improved bottom-up visual
processing, but at the cost of increasing the risk of visual
hallucination occurrence, as evidenced by our previous work
linking phosphene threshold with visual hallucination frequency
and severity.1
In summary, our findings of a double dissociation suggest a
marked deviance in visual neuronal processing between patients
with DLB who hallucinate v. healthy controls. Whether this
represents a specific loss of inhibitory drive in the visual cortex
of people with DLB and what role cholinergic function plays
remains to be clarified; neurochemical post-mortem studies or
novel spectroscopic imaging assessing for example gamma-amino-
butyric acid-ergic tone may be helpful in this regard.
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Data supplement
Table DS1 Demographic, cognitive and motor characteristics of participants included in studya
Control group
(n=19)
Dementia with Lewy
bodies group (n=16) P
Age, years: mean (s.d.) 77.6 (7.1) 81.3 (5.6) 0.10
Males:females: n 11:8 8:8 0.74
Unified Parkinson’s Disease Rating Scale, motor subscale: mean (s.d.) 0.9 (1.6) 35.0 (13.5) <0.001
Mini-Mental State Examination,13 mean (s.d.) 29.0 (1.2) 18.7 (5.1) <0.001
Cambridge Cognitive Examination (CAMCOG),14 mean (s.d.)
Total score 96.5 (3.4) 63.7 (14.4) <0.001
Executive subscore 22.1 (3.4) 9.9 (4.5) <0.001
Memory subscore 23.6 (2.1) 15.4 (4.4) <0.001
Visual acuity, decimalised: mean (s.d.) 0.64 (0.29) 0.55 (0.26) 0.33
Visuoperceptual score, % correct: mean (s.d.) 39.8 (0.4) 30.6 (6.6) <0.001
Clinician Assessment of Fluctuation,15 mean (s.d.) – 8.3 (4.4) N/A
One Day Fluctuation Assessment Scale,15 mean (s.d.) – 6.7 (4.7) N/A
Neuropsychiatry Inventory,16 hallucinations subscale: median (IQR) – 2.5 (4.5) N/A
On cholinesterase inhibitor, n – 11 N/A
On anti-Parkinsonian medication, n – 4 N/A
L-dopa dose equivalent, mg:b mean (s.d.) – 145.8 (72) N/A
N/A, not applicable.
a. For comparison of data in control participants v. participants with dementia with Lewy bodies (DLB) independent student t-tests were used for continuous data and Pearson
chi-squared for categorical data. Results in bold are significant.
b. Calculated equivalent L-dopa dose in those in the DLB group on dopaminergic medication.
group
Phosphene threshold, % Phosphene threshold, %
70.2 –
Fig. DS1 Scatter plots showing phosphene threshold plotted against V1 blood oxygen level-dependent (BOLD) activity (a) and V2/V3 BOLD
activity (b) in response to checkerboard stimulation in dementia with Lewy body (DLB, n =16) and control (n = 19) groups.
Relationship between phosphene threshold and V1 BOLD activity in the control group was positive (r=0.48, P=0.04) and negative in the DLB group (r=70.71, P=0.002) and this
was also the case for phosphene threshold v. V2/V3 BOLD activity (control group, r= 0.64, P=0.003; DLB group, r=70.57, P= 0.02). Linear fits to data (dashed – control group,
solid – DLB group) are shown for illustrative purposes.
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